Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 8/20 | 0.45 |
| ▸ | CDK1 | P06493 | 6/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.42 |
| ▸ | CDK9 | P50750 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638867 | 0.84 | CDK1 (0.58) | NPC1ALDH1A1RAB9AAURKAPDPK1 | |
| SCHEMBL6640518 | 0.83 | CDK1 (0.51) | ALDH1A1AURKAPDPK1TGFBR1ROCK1 | |
| SCHEMBL6637999 | 0.83 | NPC1 (0.51) | NPC1ALDH1A1RAB9AAURKAPDPK1 | |
| SCHEMBL6638558 | 0.83 | KMO (0.50) | NPC1ALDH1A1RAB9AAURKAPDPK1 | |
| SCHEMBL6643177 | 0.81 | KMO (0.55) | AURKAPDPK1TGFBR1ROCK1AURKB | |
| SCHEMBL7118870 | 0.79 | CDK1 (0.48) | NPC1ALDH1A1RAB9AAURKAPDPK1 | |
| SCHEMBL7112005 | 0.77 | CCNT1 (0.42) | NPC1ALDH1A1RAB9AAURKAPDPK1 | |
| SCHEMBL6642591 | 0.75 | CDK1 (0.50) | NPC1ALDH1A1RAB9AAURKAPDPK1 | |
| SCHEMBL6641629 | 0.75 | CDK1 (0.50) | NPC1ALDH1A1RAB9AAURKAPDPK1 | |
| SCHEMBL6638621 | 0.74 | CDK1 (0.53) | NPC1AURKAPDPK1KMOCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412327-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG Biomedical Institute (US) | 2004-04-28 | — | — | EP | claimed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | claimed |
| WO-2002096867-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG BIOMEDICAL INSTITUTE (US) | 2002-12-05 | — | — | WO | claimed |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-11-06 | — | — | US | disclosed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | NPC1 1115/4885ALDH1A1 3678/4885RAB9A 3067/4885 |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | NPC1 1115/4885ALDH1A1 3678/4885RAB9A 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.